Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 E102_I103del |
Therapy | Cobimetinib |
Indication/Tumor Type | histiocytosis |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 E102_I103del | histiocytosis | predicted - sensitive | Cobimetinib | Case Reports/Case Series | Actionable | In a clinical case study, Cotellic (cobimetinib) resulted in dramatic clinical improvement and decreased variant allele frequency in a patient with mixed histiocytosis harboring MAP2K1 E102_I103del, with the patient remaining disease free at least 3 years after treatment initiation (PMID: 36406830). | 36406830 |
PubMed Id | Reference Title | Details |
---|---|---|
(36406830) | Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis. | Full reference... |